PF4 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant PF4.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IP, E |
---|---|
Primary Accession | P02776 |
Other Accession | NM_002619 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG1 Kappa |
Clone Names | 3F6 |
Calculated MW | 10845 Da |
Gene ID | 5196 |
---|---|
Other Names | Platelet factor 4, PF-4, C-X-C motif chemokine 4, Iroplact, Oncostatin-A, Platelet factor 4, short form, PF4, CXCL4, SCYB4 |
Target/Specificity | PF4 (NP_002610, 31 a.a. ~ 101 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | PF4 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Platelet factor-4 is a 70-amino acid protein that is released from the alpha-granules of activated platelets and binds with high affinity to heparin. Its major physiologic role appears to be neutralization of heparin-like molecules on the endothelial surface of blood vessels, thereby inhibiting local antithrombin III activity and promoting coagulation. As a strong chemoattractant for neutrophils and fibroblasts, PF4 probably has a role in inflammation and wound repair (Eisman et al., 1990 [PubMed 1695112]).
References
Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Schuurhof A, et al. Pediatr Pulmonol, 2010 Jun. PMID 20503287. Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. Krane V, et al. Clin J Am Soc Nephrol, 2010 May. PMID 20185595. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Wiesner T, et al. Clin Exp Metastasis, 2010 Mar. PMID 20182908. CXCL4-induced monocyte survival, cytokine expression, and oxygen radical formation is regulated by sphingosine kinase 1. Kasper B, et al. Eur J Immunol, 2010 Apr. PMID 20104488.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.